RWA Wealth Partners’s Edwards Lifesciences EW Stock Holding History

RWA Wealth Partners’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$263K	Buy	3,281 +36	+1%	+$2.97K	﹤0.01%	563
2025 Q4	$277K	Buy	3,245 +59	+2%	+$4.84K	﹤0.01%	538
2025 Q3	$248K	Buy	3,186 +581	+22%	+$45.4K	﹤0.01%	563
2025 Q2	$204K	Buy	+2,605	New	+$194K	﹤0.01%	577
2025 Q1	–	Sell	-3,120	Closed	-$231K	–	555
2024 Q4	$231K	Hold	3,120	–	–	﹤0.01%	523
2024 Q3	$206K	Sell	3,120 -2,543	-45%	-$185K	﹤0.01%	541
2024 Q2	$523K	Buy	5,663 +110	+2%	+$9.74K	0.01%	386
2024 Q1	$531K	Buy	5,553 +2,433	+78%	+$204K	0.01%	390
2023 Q4	$238K	Buy	+3,120	New	+$217K	﹤0.01%	482
2023 Q3	–	Sell	-2,425	Closed	-$229K	–	378
2023 Q2	$229K	Buy	+2,425	New	+$211K	0.01%	301
2018 Q3	–	Sell	-69	Closed	-$3K	–	385
2018 Q2	$3K	Hold	69	–	–	﹤0.01%	707
2018 Q1	$3K	Buy	+69	New	+$3K	﹤0.01%	522

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

RWA Wealth Partners's EW Position: Q1 2026 in Review

RWA Wealth Partners increased its Edwards Lifesciences (EW) stake by 1.1% in Q1 2026, buying an estimated $2.97K and bringing the position to 3,281 shares worth $263K. The position accounts for ﹤0.01% of the portfolio, ranked #563.

RWA Wealth Partners first reported a position in EW in Q1 2018 and has held it in 12 quarters since. The position peaked at $531K in Q1 2024. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

RWA Wealth Partners held 3,281 shares of Edwards Lifesciences worth $263K as of Q1 2026.
RWA Wealth Partners bought 36 Edwards Lifesciences shares in Q1 2026, an estimated $2.97K.
Edwards Lifesciences made up ﹤0.01% of RWA Wealth Partners's portfolio in Q1 2026, its #563 holding.
RWA Wealth Partners first reported a position in Edwards Lifesciences in Q1 2018 and has held it in 12 quarters since.
RWA Wealth Partners's Edwards Lifesciences position peaked at $531K in Q1 2024.
1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on RWA Wealth Partners's 13F filing for Q1 2026, filed 13 May 2026.